Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

Gilead shells out $375m for immuno-oncology deal with Arcus

Gilead shells out $375m for immuno-oncology deal with Arcus

Co/MSD’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and as a combination therapy. ... CAR-T therapy for cancer Yescarta (axicabtagene ciloleucel) – acquired as part of its $12bn takeover of Kite – has been slow to

Latest news

  • EMA starts review of MorphoSys’ tafasitamab for lymphoma EMA starts review of MorphoSys’ tafasitamab for lymphoma

    Drug  could challenge Novartis and Gilead’s CAR-T therapies if approved. The EMA has started its review of MorphoSys’ anti-CD19 antibody tafasitamab (MOR208), setting up a possible challenge to ... CAR-T therapy requires the use of high-dose

  • Gilead swoops on Forty Seven with $4.9bn all-cash deal Gilead swoops on Forty Seven with $4.9bn all-cash deal

    a run of M&A that hit a peak in 2017 with Gilead’s $11.9bn acquisition of CAR-T cell therapy player Kite Pharma. ... Magrolimab complements our existing work in haematology, adding a non-cell therapy programme that complements Kite’s pipeline of cell

  • GSK pays $50m upfront to tap Immatics’ cell therapy platform GSK pays $50m upfront to tap Immatics’ cell therapy platform

    It’s a similar approach to CAR-T therapy, but according to Immatics TCRs should have broader utility because they can be targeted at proteins inside cancer cells. ... Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    The US Food and Drug Administration (FDA) has accepted an application for Bristol-Myers Squibb’s CAR-T therapy lisocabtagene maraleucel, kick-starting a priority review of the drug. ... In addition to liso-cel, BMS has another CAR-T therapy in the

  • FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

    KTE-X19 is also under regulatory review with the EMA. The US Food and Drug Administration (FDA) has begun a speedy review of Gilead subsidiary Kite's CAR-T therapy ... Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene ciloleucel) is available

More from news
Approximately 14 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... It now has more than 300 CAR-T clinical trials underway and collaboration with European and

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... In the case of a personalised therapy like CAR-T, the cost of the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH

More from intelligence
Approximately 1 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The impossible launch

    SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.

  • The balancing act that’s keeping pharma and biotech market access on its toes

    CAR-T cell therapy costs  close to $500, 000 per patient in the US, and  300, 000 in Europe. ... Zolgensma, gene therapy for the treatment of spinal muscular atrophy, is (at the time of writing) the  most expensive drug in the world at $2.1m.

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • Precision paediatrics: Treating patients with CAR-T

    Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Quick links

Infographics

Multimedia